MORNING SESSIONS |
8:00 |
SESSION IV: PHARMACOLOGY, INTENSIFICATION & RESERVOIRS
Chairs: John Coffin (Frederick, USA), Jose Gatell (Barcelona, Spain)
|
| 8:00 |
Use of Therapeutic Intensification to Probe the Source of Residual Viremia in HIV-infected Patients on
Suppressive Therapy
John Coffin (Tufts University, Boston, USA) |
| 8:20 |
Enhancing ARV Delivery to Sanctuary Sites
Vinod Labhasetwar (Lerner Research Institute, Cleveland, USA) |
| 8:40 |
Tackling HIV Reservoirs with Common-y Chain Cytokines (IL-2, IL-7, GM-CSF). Lessons Learned and Perspectives
Guido Poli (San Raffaele Scientific Institute, Milano, Italy) |
| 9:00 |
Anti-HIV-1 Nucleoside Analogue Triphosphate Levels are Significantly Lower in Primary Human
Macrophages than in Lymphocytes
Christina Gavegnano (Emory University/VA Medical Center, Decatur, USA)
|
| 9:15 |
Accelerated Decay of the HIV-1 Latent Reservoir with no Measurable Effect on Residual Viremia
after Intensificaction
with a CCR5-Antagonist
Santiago Moreno (Hospital Ramon y Cajal, Madrid, Spain)
|
| 9:30 |
Maraviroc Cerebrospinal Fluid Concentrations in HIV-1 Infection
Aylin Yilmaz (Sahlgrenska University Hospital, Gothenburg, Sweden)
|
| 9:45 |
Enhancing the Transversing Efficiency and Efficacy of the Anti Retroviral Drug “Saquinavir” using
Nanotechnology:
Implications for Nanotherapeutics in Neuro-Aids
Supriya Mahajan (State University of New York at Buffalo, Buffalo, USA)
|
10:00 |
Break |
|
10:30 |
SESSION V: CLINICAL IMPLICATIONS OF COMPARTMENTS & RESERVOIRS
Chairs: Jose Gatell (Barcelona, Spain), Alain Lafeuillade (Toulon, France) |
| 10:30 |
An Update on HIV Persistence in Gut Mucosa
Satya Dandekar (University of California, Davis, USA) |
| 10:50 |
The Central Nervous System as a Reservoir
Scott Letendre (University of California, San Diego, USA) |
| 11:10 |
Is the Genital Tract a Distinct Compartment?
Pietro Vernazza
(Kantonsspital, St. Gallen, Switzerland) |
| 11:30 |
Early Genital Tract Compartmentalization during Acute SIV Infection
James Whitney (Beth Israel Deaconess Medical Center, Boston, USA)
|
| 11:45 |
No Decay in HIV-infected Naive CD4+ T-cells Following Antiretroviral Therapy (ART): a Persistent
Long Term Reservoir
Sharon Lewin (Alfred Hospital, Melbourne, Australia)
|
| 12:15 |
Therapy Failure Following Selection of Enfuvirtide Resistant HIV-1 in Cerebrospinal Fluid in a Patient
with Suppressed Plasma HIV-1 RNA Levels
Monique Nijhuis (University Medical Center Utrecht, Utrecht, the Netherlands)
|
| 12:30 |
Lunch |
AFTERNOON SESSIONS |
| 14:00-16:00 |
Poster Viewing Session II |
| 16:00 |
SESSION VI: RESEARCH PRESENTATIONS FROM FIRMS SUPPORTING THE MEETING
Chairs: Alain Lafeuillade (Toulon, France), Daniel Zagury (Paris, France) |
| 16:00 |
Abbott Virology Update
On behalf of Abbott:
Chris Woodward (Sinking Spring, USA) |
| 16:15 |
Interest of Ultrasensitive Viral Load
On behalf of Boheringer Ingelheim:
Jacques Izopet (Toulouse, France) |
| 16:30 |
Combined Development of an HIV Integrase Inhibitor with a Novel Pharmacoenhancer
On behalf of Gilead Sciences, Inc.:
Romas Geleziunas (Foster City, USA) |
| 16:45 |
Drug Hunting for HIV Eradication Molecules
On behalf of Tibotec:
Guenter Kraus (Mechelen, Belgium) |
| 17:00 |
SESSION VII: PRIMARY HIV INFECTION & ERADICATION ISSUES
Chairs: Dean Hamer (Bethesda, USA), David Margolis (Chapel Hill, USA) |
| 17:00 |
Persistence CD4+T Cell Depletion and Immune Activation in the GI Tract of Acutely Infected Individuals
Treated with Combination ART does not Appear to be Caused by Cryptic Ongoing Viral Replication
Martin Markowitz (Aaron Diamond Center, New York, USA) |
| 17:20 |
HIV Eradication by Stem Cell Transplantation: is it Feasible?
Gero Hütter (Charité Campus Benjamin Franklin, Berlin, Germany) |
| 17:40 |
Eradication of HIV Infection: Any Problem, However Complicated, if Looked at in the Right Way,
becomes More Complicated
David Margolis (University of North Carolina at Chapel Hill, Chapel Hill, USA) |
| 18:00 |
Purging the HIV-1 Reservoir through the Disruption of the PD-1 Pathway
Sandrina Da Fonseca (Université de Montréal, Montréal, Canada) |
| 18:15 |
Durable Aviremia after Discontinuation of Prolonged HAART Initiated at PHI
Sabine Kinloch-de Loes (Royal Free and University College Medical School, London,
United Kingdom) |
| 18:30 |
Poster Discussion Session
Chairs: Alain Lafeuillade (Toulon, France),
David Margolis (Chapel Hill, USA),
Mario Stevenson (Worcester, USA) |
| 18:30 |
Tissue Viral Dynamics in SIV Infected Macaques with Highly Active Antiretroviral Therapy (HAART)
Olivier Bourry (GERHM-Inserm U625, Rennes, France) |
| 18:35 |
An In Vitro System to Model HIV-1 Latency
Fabio Romerio (Institute of Human Virology, Baltimore, USA) |
| 18:40 |
Latent HIV Infection can be Established in Resting CD4+ T-cells In Vitro Following Incubation with
Multiple Diverse Chemokines which Facilitate Nuclear Import of the Pre-integration Complex
Sharon Lewin (Alfred Hospital, Melbourne, Australia) |
| 18:45 |
P21 (WAF1/CIP1) Inhibits HIV-1 Infection of CD4+ T Cells and is Overexpressed in “Elite” Controllers
Mathias Lichterfeld (Massachusetts General Hospital, Boston, USA) |
| 18:50 |
Monocytes to Macrophages Differentiation Confers Resistance to HIV-Vpr Induced Apoptosis: Role of
Antiapoptotic Bcl2 and Inhibitors of Apoptotsis (IAP) Proteins
Ashok Kumar (Children’s Hospital of Eastern Ontario, University of Ottawa,
Ottawa, Canada) |
| 18:55 |
Syndecan-1 Expression and Microbial Translocation in HIV-1 Infection
Anthony Smith (University of Minnesota, Minneapolis, USA) |
| 19:00 |
Constitutive Expression of TRIM22 Inhibits HIV-1 LTR-dependent Transcription and Contributes to
Inefficient X4 HIV-1 Replication in U937 Cell Subclones
Guido Poli San Raffaele Scientific Institute, Milano, Italy) |
| 19:05 |
Ex Vivo, BIT225 Inhibits the Spread and Transfer of HIV-1 from the Infected Monocytes of HIV-1
Seropositive Individuals
John Wilkinson (Biotron Limited, Sydney, Australia) |
| 19:10 |
Discussion |
| 20:00 |
Gala Dinner |
